Explore Drug Development

From idea to medicine.

New treatments, clinical milestones, and the people moving medicine forward.

Start exploring.

Drug Development

Eli Lilly sweeps top spots in pharmaceutical industry rankings

Eli Lilly has just achieved a rare milestone in the pharmaceutical world. For the first time, a single drug company has claimed the number one spot in two major industry metrics simultaneously. The IDEA Pharma index placed Eli Lilly at the very top of its lists for both innovation and invention. What exactly do these two categories measure? According to the index, innovation focuses on commercial success and major milestones. It evaluates how much revenue a company is generating from new products and how many new drugs it has successfully guided through the approval process. On the other hand, the invention category looks toward the future. It measures a company's overall investment in research and development, the volume of its clinical trials, and the strength of its drug pipeline from early testing to late-stage studies. However, readers should keep in mind that these findings come from a private consultancy firm rather than peer-reviewed scientific research. Because the complete methodology is behind a paywall, the exact math used to rank these companies is not fully transparent.

STAT News1 min read

Drug Development

Blocking the IDOL Enzyme Could Protect the Brain from Alzheimer's

Scientists have uncovered a new potential way to fight Alzheimer's disease by targeting a newly identified enzyme known as IDOL. An enzyme is a protein that helps speed up chemical reactions in the body. Researchers have established that this specific enzyme plays a major role in the disease, making it a highly promising focus for new medical treatments. When scientists removed the IDOL enzyme from neurons, which are the primary nerve cells in the brain, they observed a sharp reduction in amyloid plaques. These plaques are sticky clumps of proteins that famously build up and cause damage in an Alzheimer's patient's brain. Beyond simply clearing out these toxic clumps, eliminating the enzyme actually improved vital brain processes. It boosted the overall resilience of the cells and helped them communicate with one another more effectively. However, it is crucial to recognize that these findings are still in the very early stages of discovery. The current reports do not disclose specific details like sample sizes, exact quantitative data, or whether the tests were performed in living animals or isolated cells in a lab. The scientific community will need to conduct much more early-stage research before this approach reaches human patients.

Science Daily1 min read

Drug Development

Alzheimer's Research is Surging, But Clinical Challenges Remain

Alzheimer's disease research is entering a busy new chapter. As of early 2025, scientists are running more than 180 clinical trials to find better ways to treat the condition. Much of the recent spotlight has been on immunotherapies, which harness the immune system to fight the disease. Specifically, drugs like lecanemab and donanemab target and reduce clumps of a protein in the brain called amyloid beta. These protein clumps, known as plaques, are a major hallmark of Alzheimer's. While clearing these plaques is a significant scientific step, researchers are careful to note the limitations of current treatments. For patients in the early stages of the disease, these amyloid-targeting drugs only modestly preserve memory and daily functioning. Because of this, scientists are also testing treatments aimed at tau, another protein that causes problems in the Alzheimer's brain. Early studies of tau-targeted vaccines, antibodies, and genetic tools called antisense oligonucleotides show that these experimental treatments are generally well tolerated by patients.

PubMed1 min read

Drug Development

New Cell Model Helps Discover Drugs for Chemo Nerve Damage

Chemotherapy is a crucial treatment for cancer, but it frequently causes severe side effects. One of the most difficult is chemotherapy-induced peripheral neuropathy, a condition that damages the nerves and causes debilitating pain and numbness. Because scientists have lacked good laboratory models of human nerves, finding treatments to prevent this damage has been challenging. To solve this, researchers built a new testing platform using human induced pluripotent stem cells. These are regular adult cells that have been reprogrammed to grow into human sensory nerves. This gave the team a scalable and reliable way to study how paclitaxel, a common chemotherapy drug, causes nerve toxicity and damage. With this new cellular testing ground, the research team went hunting for protective drugs. They rapidly screened a library of 192 compounds known as kinase inhibitors, which are drugs that block specific proteins involved in cell communication. Out of this batch, they identified 19 compounds that successfully shielded the nerves from chemotherapy damage. By genetically altering the cells, they discovered that protecting the nerves specifically required blocking a combination of three enzymes at the same time: MAP4K4, MINK1, and TNIK. To confirm their findings, the researchers used targeted drugs to block those three specific enzymes. This approach successfully stopped nerve degeneration in their human cell models. Furthermore, the targeted treatment preserved nerve health and fiber density in a living mouse model experiencing chemotherapy-induced nerve damage.

PubMed2 min read

Drug Development

Atom-by-atom scanning speeds up the search for new medicines

Finding a new drug is like searching for a microscopic key to fit a specific protein lock. Scientists use computers to screen giant libraries of small molecules to find a match, a process called virtual screening. Traditionally, they test each molecule one by one using a method called molecular docking. But with modern databases containing billions of compounds, checking every single pair takes far too long. Recent artificial intelligence models tried to speed this up by compressing an entire protein and an entire molecule into single mathematical summaries, then checking if those summaries match. While faster, this whole-molecule approach misses the subtle, partial ways molecules might fit together. Enter Simpatico, a newly developed open-source software that zooms in closer. Instead of summarizing the whole molecule, Simpatico assigns a unique mathematical signature, or embedding, to every single atom in the protein and the potential drug. By comparing at the atomic level, Simpatico searches a massive database to find atoms that perfectly complement the target protein. According to the researchers, this approach bypasses the need to test each pair individually. In tests, Simpatico ran orders of magnitude faster than traditional methods and achieved top-tier accuracy. Remarkably, it managed this high performance despite being trained on a relatively small dataset of about 15,000 examples and without relying on complex 3D shape predictions.

bioRxiv2 min read

Drug Development

Regeneron Inks $2.3 Billion Deal to Hit Hidden Disease Targets

Regeneron and Parabilis are teaming up on a $2.3 billion project to create an entirely new class of medicine. They plan to build Antibody-Helicon Conjugates, a technology that works like a highly specific guided delivery system. Regeneron will provide the antibodies, which act as a navigation system to find and bind to specific diseased cells. Parabilis will provide the cargo, known as Helicons. These are specialized miniature proteins designed to slip inside cells and block disease triggers that traditional chemical drugs simply cannot reach. The partnership is starting with five specific disease targets, though these candidates remain in the earliest stages of laboratory discovery. Parabilis does have preliminary data from its own standalone experimental drug, zolucatetide. In an early trial, this drug reduced the diameter of a rare connective tissue tumor by 52.2 percent. However, this exciting result comes with a major caveat because the efficacy data is severely limited by a single-patient sample size. Scientists will need much more testing to prove the drug is truly effective. While Regeneron is looking to the future with this massive new deal, it also recently faced a major hurdle in its existing pipeline. The company announced the failure of a late-stage clinical trial testing a combination of two immune system drugs, fianlimab and cemiplimab, for advanced melanoma. The therapy missed its primary goal of improving progression-free survival, meaning it failed to prevent the skin cancer from worsening compared to standard treatments.

GEN2 min read

Drug Development

Old Drugs, New Tricks: Repurposing Medicines for Pandemics

When a new virus emerges, developing a treatment from scratch takes years. To speed things up, scientists often look at existing medications to see if they can fight new threats, a process known as drug repurposing. A recent sweeping review, called a horizon scan, searched medical literature and clinical trial databases to see how many existing drugs are being tested against viruses with pandemic potential. The researchers found 196 repurposed drug candidates in the scientific literature, with 58 currently in active clinical development. These investigated medicines mostly fall into categories like direct-acting antivirals, which stop viruses from multiplying, alongside medications that calm the immune system and reduce inflammation. However, the study revealed that active human testing is highly concentrated. Almost all interventional clinical trials are restricted to just two viruses: SARS-CoV-2 and influenza. Specifically, 29 treatments for SARS-CoV-2 and two for influenza have made it to advanced Phase III trials, which is the final testing step before general approval. For other highly dangerous viruses like Ebola, Marburg, MERS, and mpox, the research is lagging. Potential treatments for these diseases are still stuck in early exploratory or laboratory testing phases. The study authors also strongly caution that just because a drug is being investigated does not mean it will actually work. Before any repurposed medicine can be given to patients, it still requires rigorous lab validation and testing to prove it is safe, effective, and behaves correctly in the human body.

PubMed2 min read

Drug Development

Meet the AI Scientists Accelerating Medical Research

Tech organizations like Google DeepMind and Edison are building "AI scientists" to act as digital research partners. Recently detailed in the journal Nature, these new artificial intelligence tools aim to automate the traditional scientific process. Instead of just answering simple questions, these programs can generate original hypotheses, design lab experiments, and interpret complex data to help human researchers solve biological mysteries. The early results are highly promising. DeepMind's tool, called Co-Scientist, has successfully identified new potential targets for treating liver scarring and predicted ways to repurpose existing drugs for a severe blood cancer known as acute myeloid leukemia. Similarly, Edison's AI, named Robin, proposed novel ways to treat a common blinding eye condition called dry age-related macular degeneration. Impressively, Robin's unique treatment ideas were later tested and validated in lab experiments using real human eye cells. Building on this momentum, Edison has introduced an upgraded platform called Kosmos. This system is already partnering with the pharmaceutical company Incyte to sort through massive amounts of medical evidence and build predictive models for new therapies currently in the company's development pipeline.

GEN1 min read

Drug Development

Weight loss on Ozempic is linked to major drops in disease risk

Drugs like Ozempic, Wegovy, Mounjaro, and Saxenda have made headlines for helping people shed pounds. But recent research shows that successfully losing weight on these medications comes with profound medical benefits. Patients who lost a significant amount of weight saw a sharp drop in their risk for serious conditions, specifically kidney disease and sleep apnea, a disorder where a person's breathing repeatedly stops and starts during sleep. On the other hand, the outcomes were concerning for patients who actually gained weight while taking these medications. This group faced a higher risk of developing severe complications related to obesity. Heart failure was a particularly prominent risk for those who gained weight despite the medical intervention. A major hurdle to seeing these positive health results is simply staying on the medication. The researchers noted that a large number of patients quit taking the drugs within their first year. While the overall findings are compelling, it is important to view them with a bit of caution for now. The current data lacks details on the exact number of participants, their specific backgrounds, and the precise mathematical changes in their health risks.

Science Daily1 min read

Keep connecting the dots.

All topics ↗

Start exploring.

Keep connecting the dots.

Oncology ↗

General Biotech ↗

Immunology ↗

A little science goes a long way.